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The BCL10 gene (CIPER, Koseki et al, 1999; c-CARMEN, Thome
et al, 1999; mE10, Yan et al, 1999) was originally identified as the
gene that becomes fused to the IgH locus in MALT B-cell
lymphomas as a consequence of the t(1;14)(p22;q32) translocation
and is a cellular homologue of the equine herpes virus-2 E10 gene
(Willis et al, 1999; Zhang et al, 1999). Both encode proteins that
contain an amino terminal caspase recruitment domain (CARD)
similar to that found in some apoptotic regulatory proteins
(Hoffman et al, 1997). The BCL10 gene in lymphomas with the
t(1;14) translocation was altered by frameshift mutations that
resulted in truncation of the BCL10 protein beyond the CARD
domain. It was suggested that these mutations might arise as a
consequence of the Ig gene somatic hypermutation mechanism
(Migliazza et al, 1995; Matolcsy et al, 1996). Mutations resulting
in similarly truncated proteins were also reported in cDNA clones
from 3/3 mesothelioma and 3/3 germ cell tumour cell lines, and in
genomic DNA from 2/25 colorectal adenocarcinomas. In contrast,
mutation was not observed in 15 breast carcinomas, 11 pancreatic
adenocarcinomas or 15 lung carcinoma cell lines. Willis et al
(1999) also showed that wild-type BCL10 protein could induce
apoptosis; however, the truncated BCL10 protein failed to induce
apoptosis and exhibited transforming activity. In the current study
we have extended the investigation of the occurrence of BCL10
mutations to other tumour types, including prostate carcinoma,
small-cell lung cancers, head and neck tumours, kidney cancer and
sarcomas.
METHODS
Tumour samples and cell lines
Prostate tissue from patients undergoing either transurethral resec-
tion of prostate or radical prostatectomy, was either immediately
frozen (71/87 of the samples) or preserved by formalin fixation
(16/87 of the samples). Microdissection of frozen material was
carried out as described previously (Macintosh et al, 1998) on
haematoxylin and eosin (H&E) stained sections using a glass
needle. Alternatively, where larger areas of tumour were apparent,
microdissection was carried out by hand using a scalpel. Micro-
dissection of paraffin-embedded material was carried out on five
parallel 10 mm sections stained with toluidine blue. Foci of carci-
noma were excised and the histology examined in an adjacent 5 mm
section stained with H&E. All prostate carcinomas were graded
G1–4 according to D’Amico et al (1998). The grading pattern for
this set of samples was G0 6/87 (7%), G1 4/87 (5%), G2 43/87
(49%), G3 14/87 (16%), G4 14/87 (16%), ungraded 6/87 (7%).
The two prostate carcinoma cell lines examined were LNCaP
and PC3. Fifteen small-cell lung cancer cell lines were examined
HTB119, HTB120, HTB171, HTB173, HTB175, HTB180,
HTB184, CRL 2049, CRL 2062, CRL 2064, CRL 2066, CRL
5804, CRL 5808, CRL 5809 and CRL 5811. Eighteen clear cell
renal carcinoma cell lines were examined UOK101, 102, 108, 111,
122, 125, 126, 138, 139, 140, 141, 147, 151, 154, 161, 170, 171
and 180. Six papillary renal cell carcinoma cell lines were exam-
ined UOK109, 120, 124, 145, 112 and 132. The first four of these
are known to contain translocations involving the TFE3 gene
(Sidhar et al, 1996; Clark et al, 1997). Eleven sarcoma cell lines
examined were STS255, Fuji, HS-SY-II and A2243 synovial
sarcomas; A204, RMS and A673 rhabdomyosarcomas; MNNG-
HOS chemically transformed human osteosarcoma line; HT1080
and HTB152 fibrosarcomas; RD-ES and HTB86 Ewings sarcomas
and the HTB88 leiomyosarcoma. The SK-N-BE and TN2 neuro-
blastoma cell lines, A431 epidermoid carcinoma cell line, the
SK23 melanoma cell line and BT474 breast carcinoma cell lines
were also examined.
A series of 20 head and neck squamous cell cancers consisting
of index tumours of various sites from 16 patients and four second
tumours that had developed within the head and neck region (more
than 3 years from the original diagnosis) were also screened.
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Correspondence to: S GillThese tumours were graded G1–3 as follows: G1 4/20; G2 8/20;
G3 4/20; ungraded 4/20. DNA was extracted from archival
material.
Cell lines were from the American Tissue Culture Collection
(ATCC), except for the UOK lines (kindly provided by Dr WM
Linehan) (Anglard et al, 1992), RMS (Garvin et al, 1986), Fuji
(Nojima et al, 1990), A2243 (kindly provided by Dr SA
Aaronson), HS-SY-II (Sonobe et al, 1992) and TN2 (Yaoita et al,
1989) DNA was extracted from microdissected material and cell
lines by established methods (Sambrook et al, 1989).
SSCP analysis
Exons 1, 2 and 3 of BCL10 were amplified by polymerase chain
reaction (PCR) from genomic DNA using Hotstar Taq DNA poly-
merase (Quiagen) and the five primer sets (1, 2.1, 2.2, 3.1 and 3.2)
described by Willis et al (1999). Following an initial incubation at
95°C for 15 min for enzyme activation the cycle conditions for the
first five cycles were as follows: 94°C for 30 s, 65–55°C for 30 s
(decreasing by 2.5°C per cycle) and 72°C for 1 min. The subse-
quent 35 cycles were 94°C 1 min, 55°C 1 min and 72°C 1 min,
followed by a final step of 72°C for 5 min. For single-strand
conformation polymorphism (SSCP) analysis PCR products (2 ml)
were mixed with 4 ml formamide loading buffer and separated in
the Genphor electrophoresis system (Pharmacia-Amersham, UK)
under 15 W constant power for 2–3 h at 5°C. Bands were
visualized by silver staining. DNA from the follicular lymphoma
sample, G0109, was kindly provided by MJS Dyer for use as
a positive control with exon 3.2 SSCP gels.
Direct sequencing
Abnormal bands were excised from SSCP gels and heated in 50 ml
water at 95°C for 10 min. One microlitre of eluate was used to
reamplify the mutant product using the same primers and condi-
tions. Reamplified products were excised from agarose gels,
purified using a gel extraction kit (Quiagen) to remove primer
dimers and excess nucleotides and sequenced in both directions
using an ABI Prism Dye Terminator Cycle Sequencing Kit
containing Amplitaq DNA polymerase FS (Perkin-Elmer)
according to manufacturer’s instructions.
RESULTS
In this study we have examined 81 prostate primary prostate carci-
nomas as well as the LNCaP and PC3 prostate carcinoma cell
lines. Primary prostate carcinomas were microdissected from
frozen or formalin-fixed specimens prior to genetic analysis in
order to minimize contamination from normal tissue. Six speci-
mens of benign prostatic hyperplasia were added to this series.
Fifteen small-cell lung carcinoma cell lines, 24 renal cell carci-
noma cell lines, 20 squamous cell carcinomas of the head and neck
and 13 soft tissue sarcoma cell lines were also examined. Also
included in this series were cell lines from two neuroblastomas, an
epidermal carcinoma, a melanoma and a breast carcinoma.
To screen for mutations in the BCL10 gene we have adopted the
same PCR-SSCP based method utilized by Willis et al (1999). The
full coding sequence of the BCL10 gene was amplified by five
different PCR reactions with a single PCR product spanning
exon 1 and two reactions spanning each of the remaining two
exons. This technique can detect mutations down to a sensitivity of
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Figure 1 (A) Examples of silver stained ‘Genophor’ SSCP gels of 12
prostate carcinoma specimens for each of the five BCL10 exon fragments.
Arrows denote bandshifts corresponding to polymorphic loci. Lane 5 of exon
3.2 contains the follicular lymphoma sample G0109 which harbours a
deletion in exon 3.2 (Willis et al, 1999). For exon 3.2, lane 1 shows a failed
PCR reaction, whilst lane 6 is a negative (water) control. (B) Silver-stained
SSCP gels of exon 3.2 samples showing bandshifts attributed to a
polymorphism. Lane 1 normal lymphocyte sample 1; lane 2 A431; lane 3
A204; lane 4 A2243; lane 5 G0109 as per (A); lane 6 HS-SY-II; lane 7 Fuji;
lane 8 STS255; lane 9 UOK122; lane 10 UOK161; lane 11 UOK154; lane 12
normal lymphocyte sample 2one mutant allele in ten normal alleles and other screening projects
in our laboratory have yielded detection rates of 90% (Condie et al,
1993).
Analysis of exon 1 identified several abnormally migrating
bands in SSCP gels. Each abnormal band was, however, present in
many samples indicating that they represent polymorphisms rather
than true mutations (Figure 1A). Sequencing all of the abnormal
bands demonstrated that the alterations correspond to a silent
CTG-CTC mutation at codon 8 and a G®C alteration 11 bases
downstream from exon 1 within intron 1. These were either found
alone or in combination. SSCP analysis of exon 2 and of the 5¢
region of exon 3 failed to yield abnormally migrating bands.
Finally, analysis of the 3¢-region of exon 3 yielded a single
abnormal band, which again was present in many samples
(Figure 1B). This band was sequenced and found to correspond to
a previously characterized GGA(gly)®GAA(glu) polymorphism
at codon 213 (TG Willis, personal communication). Thus we failed
to detect somatic mutations of BCL10 in the tumour series
examined in this study.
DISCUSSION
It is now generally accepted that cancer development is a multistep
process requiring the accumulation of mutations in several distinct
genes. Alterations in these genes may have a variety of biological
consequences, including constitutive activation of cellular control
pathways, removal of cell cycle check points, removal of mecha-
nisms which monitor DNA damage and interference with
mechanisms that control entry into the apoptotic pathway (Lane,
1992; Vogelstein and Kinzler, 1993; Kinzler and Vogelstein,
1997). Mutations in the BCL10 gene are believed to fall within the
latter category of alterations and represented the first example of
alterations of a protein containing a CARD domain in human
cancer development. Willis et al (1999) found that mutations
within the BCL10 gene in human malignancy resulted in truncated
BCL10 proteins that were no longer able to promote entry into
apoptosis.
Willis et al (1999) reported a high frequency of BCL10 muta-
tions, in particular groups of malignancies including MALT
lymphomas, follicular lymphomas, germ cell tumours and
mesotheliomas, but much lower levels of mutations in other
tumour classes such as lung cancer and colorectal cancer. The
results presented in the current study are in agreement with these
observations since we failed to detect alterations of the BCL10
gene in small-cell lung cancer. In addition we have identified other
groups of malignancies including clear cell and papillary renal
carcinoma, prostate cancer and human sarcomas that also exhibit
low frequencies of BCL10 mutations. A limitation of the current
study is that the SSCP may miss some mutations thus the occur-
rence of a low level of mutation within these tumour groups cannot
be excluded. When the data are considered together it would,
therefore, appear that alterations of BCL10 may be restricted to
particular classes of human malignancy. Additional studies are
required on other types of cancer to determine the exact distribu-
tion of BCL10 mutations in neoplasia.
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